Enlargement of the Axial Length and Altered Ultrastructural Features of the Sclera in a Mutant Lumican Transgenic Mouse Model.

Lumican (LUM) is a candidate gene for myopia in the MYP3 locus. In this study, a mutant lumican (L199P) transgenic mouse model was established to investigate the axial length changes and ultrastructural features of the sclera. The mouse model was established by pronuclear microinjection.

Effect of a Single Nucleotide Polymorphism in the LAMA1 Promoter Region on Transcriptional Activity: Implication for Pathological Myopia.

Purpose: To elucidate the role of the protein coding laminin α1 (LAMA1) gene in pathological myopia (PM) at the transcriptional level. To achieve this, the binding affinity of single nucleotide polymorphism (SNP) rs2089760-located on the LAMA1 promoter gene-to human fetal scleral fibroblast (HFSF) nucleoprotein was investigated and its effect on LAMA1 transcriptional initiation activity was analyzed.

Methods: Binding interactions of the HFSF nucleoprotein and biotin-labeled SNP rs2089760 probe were investigated by amplifying the LAMA1 promoter gene and performing overlap extension polymerase chain reaction (PCR) to obtain the G/A mutation of LAMA1 SNP rs2089760.

Distribution of bacterial keratitis and emerging resistance to antibiotics in China from 2001 to 2004.

Objective: To study on the distribution of bacterial keratitis isolates and the resistance to antibiotics in China from 2001 to 2004.

Methods: 1985 specimens from the bacterial keratitis at the Beijing Tong Ren Eye Center were cultured and identified. In vitro susceptibility testing of positive isolates to antibiotics was determined by the Kirby-Bauer disk diffusion method and interpreted according to Clinical and Laboratory Standards Institute.

Pharmacokinetics of chlorhexidine gluconate 0.02% in the rabbit cornea.

Purpose: The aim of this study was to determine the pharmacokinetic parameters of chlorhexidine gluconate (CHG) in the rabbit cornea.

Methods: Each eye of 16 New Zealand white rabbits were topically instilled with 50 microL of CHG 0.02% eye drops twice with a 5-min interval.